Implementation of dupilumab in routine care of atopic eczema: results from the German national registry <scp>TREAT</scp> germany

Authors :: Abraham, S.
Haufe, E.
Harder, I.
Heratizadeh, A.
Kleinheinz, A.
Wollenberg, A.
Weisshaar, E.
Augustin, M.
Wiemers, F.
Zink, A.
Biedermann, T.
von Kiedrowski, R.
Hilgers, M.
Worm, M.
Pawlak, M.
Sticherling, M.
Fell, I.
Handrick, C.
Schäkel, K.
Staubach, P.
Asmussen, A.
Schwarz, B.
Bell, M.
Neubert, K.
Effendy, I.
Bieber, T.
Homey, B.
Gerlach, B.
Tchitcherina, E.
Stahl, M.
Schwichtenberg, U.
Rossbacher, J.
Buck, P.
Mempel, M.
Beissert, S.
Werfel, T.
Weidinger, S.
Schmitt, J.
TREATgermany study group
Source :: Br. J. Dermatol., DOI: 10.1111/bjd.18958 (2020)
Publication Year :: 2020
Publisher :: Oxford University Press (OUP), 2020.
Abstract: The German atopic eczema (AE)-registry TREATgermany is a non-interventional multicenter patient cohort study for adult patients with currently moderate-to-severe disease activity or current/previous anti-inflammatory systemic treatment.1,2 Dupilumab has demonstrated to be an effective treatment for patients with moderate-to-severe AE in clinical trials.3-5 Real world evidence is now needed to evaluate its effectiveness and safety in routine care.

Subjects :: medicine.medical_specialty
business.industry
Eczema
MEDLINE
Dermatology
Antibodies, Monoclonal, Humanized
Dupilumab
language.human_language
Dermatitis, Atopic
German
Family medicine
language
Humans
Medicine
Registries
National registry
business
Routine care

Full Text Access

Tools